FDA’s Ganley “Disappointed” By Competitive Pain Reliever Marketing
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC head Charles Ganley, MD, chastised OTC pain reliever marketers for airing comparative DTC ads in the wake of COX-2 safety concerns during a speech May 6 at the Consumer Healthcare Products Association Regulatory & Scientific Conference in Washington, D.C